BeOne’s BGB-16673 Gets EMA PRIME for Waldenstrom’s
Decision highlights the promise of BGB-16673, an investigational and potentially first-in-class BTK degrader designed to overcome resistance and deepen responses in B-cell malignancies BeOne Medicines...
